Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?

• Status: Unknown status
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines

1. whether adding vitamin D, a potent immunomodulator, could improve viral response and shorten treatment duration (from 24 weeks to 12 weeks)

2. whether Vitamin D levels predictes negative treatment outcome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziv Hospital
• Collaborator: Hillel Yaffe Medical Center
• Treatments: Ergocalciferols; Ribavirin; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 18 to 65 years of age,

• Chronic genotype 2,3 HCV infection, Traetment Naive

• Negative sero for HBV, HDV and HIV viral infections

• Absolute neutrophil count of >1500 per cubic millimeter, a platelet count of >90,000 per cubic millimeter

• Normal hemoglobin level

Exclusion Criteria:

• Decompensated liver disease (cirrhosis with CP score >9)

• Another cause of clinically significant liver disease

• Hepato cellular carcinoma

• Psychiatric Disorder

• Chronic heart failure

• Pregnant women

• Uncontrolled diabetes with retinopathy

• Arythmia

• Active CAD

• Positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease